C84.72 Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes

Name of the Condition

• Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes (ICD-10 Code: C84.72)

Summary

Anaplastic large cell lymphoma (ALCL), ALK-negative, intrathoracic lymph nodes, is a rare type of non-Hodgkin lymphoma that originates from T-cells or null cells. It is characterized by the presence of large, abnormal lymphoid cells and typically presents as a systemic disease, though cutaneous involvement may occur. The condition is aggressive and requires prompt evaluation and management.

Causes

The exact cause of ALK-negative ALCL is not fully understood. It is believed to involve genetic mutations in lymphoid cells, which lead to uncontrolled growth and accumulation. Environmental factors or chronic antigen stimulation may contribute to its development, though specific triggers remain unclear.

Risk Factors

• Age: More common in adults, particularly those over 60.
• Immunosuppression: Conditions or treatments that weaken the immune system.
• Genetic predispositions: Family history of lymphoma or related disorders.
• Prior lymphoid disorders: History of other lymphoid malignancies may increase risk.

Symptoms

• Swollen lymph nodes or masses in affected areas.
• Fever, night sweats, and unexplained weight loss (B symptoms).
• Skin lesions, rashes, or nodules (if cutaneous involvement is present).
• Fatigue, loss of appetite, and general malaise.
• Organ-specific symptoms (e.g., cough, chest pain, or shortness of breath if intrathoracic lymph nodes are involved).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans), and tissue biopsy. Histopathological examination of the biopsy sample is critical to identify the characteristic large, abnormal lymphoid cells. Immunohistochemistry and molecular testing may be used to confirm the ALK-negative status and rule out other lymphomas.

Treatment Options

Treatment typically includes systemic chemotherapy, often with regimens used for other aggressive lymphomas. Targeted therapies or immunotherapies may be considered based on individual patient factors. Radiation therapy may be used for localized disease or to address specific symptoms. Treatment plans are tailored to the patient’s overall health and disease extent.

Prognosis and Follow-Up

Prognosis varies depending on factors such as age, overall health, and response to treatment. Regular follow-up is essential to monitor for recurrence or progression. Long-term surveillance may include periodic imaging and clinical assessments.

Complications

Potential complications include disease progression, treatment-related side effects (e.g., infection, organ toxicity), and recurrence. Advanced disease may lead to organ dysfunction or failure.

Lifestyle & Prevention

No specific preventive measures are known. Maintaining a healthy lifestyle, avoiding known carcinogens, and managing underlying immune conditions may support overall health. Regular medical check-ups are recommended for early detection of any abnormalities.

When to Seek Professional Help

Seek medical attention if you experience persistent symptoms such as unexplained weight loss, fever, night sweats, or swollen lymph nodes. Prompt evaluation is important for timely diagnosis and treatment.

Tips for Medical Coders

When coding for C84.72, ensure the documentation specifies "ALK-negative" and "intrathoracic lymph nodes" to accurately reflect the condition. Verify that the site of involvement is clearly documented to distinguish it from other lymph node locations. Review clinical notes for confirmation of histopathological findings and ALK status to support code assignment.